Endometrial Cancer Trial Drug Now Free
Felixthecat
Member Posts: 37
Endometrial Cancer Trial Drug Now Free
http://www.cancerwise.org/may_2005/display.cfm?id=1A29F5A7-F64B-4656-9FF3A93B491655CF&method=displayFull&color=green
Women with endometrial cancer will no longer have to pay for a drug being studied in a hormonal therapy clinical trial. Thanks to funding from a $10.4 million Specialized Program of Research Excellence (SPORE) grant, M. D. Anderson study investigators hope to recruit more women in a Phase II clinical trial for Mifepristone as a treatment for specific types of endometrial cancer. Before the SPORE funding became available from the National Cancer Institute, study participants had to pay $500 a month to cover the costs of the drug.The goal of the study is to determine the potential benefit of Mifepristone for recurrent or advanced endometrial cancer patients with tumors that are sensitive to estrogen (progesterone-receptor positive) or patients with low-grade endometrial stromal sarcoma (LGESS), a less common cancer that develops in the supporting connective tissue of the endometrium....(more info via link above).
Details of the Clinical Trial:
Mifepristone for Patients With Endometrial Cancer and LGESS
This study is currently recruiting participants. Verified by M.D. Anderson Cancer Center, July 2007
http://clinicaltrials.gov/ct2/show/NCT00505739?cond="Carcinoma,+Endometrioid"&rank=3
Phase II Study of Mifepristone (RU-486) in the Treatment of PR Positive Advanced/Recurrent Endometrioid Adenocarcinoma and Low Grade Endometrial Stromal Sarcoma (LGESS)
http://www.cancerwise.org/may_2005/display.cfm?id=1A29F5A7-F64B-4656-9FF3A93B491655CF&method=displayFull&color=green
Women with endometrial cancer will no longer have to pay for a drug being studied in a hormonal therapy clinical trial. Thanks to funding from a $10.4 million Specialized Program of Research Excellence (SPORE) grant, M. D. Anderson study investigators hope to recruit more women in a Phase II clinical trial for Mifepristone as a treatment for specific types of endometrial cancer. Before the SPORE funding became available from the National Cancer Institute, study participants had to pay $500 a month to cover the costs of the drug.The goal of the study is to determine the potential benefit of Mifepristone for recurrent or advanced endometrial cancer patients with tumors that are sensitive to estrogen (progesterone-receptor positive) or patients with low-grade endometrial stromal sarcoma (LGESS), a less common cancer that develops in the supporting connective tissue of the endometrium....(more info via link above).
Details of the Clinical Trial:
Mifepristone for Patients With Endometrial Cancer and LGESS
This study is currently recruiting participants. Verified by M.D. Anderson Cancer Center, July 2007
http://clinicaltrials.gov/ct2/show/NCT00505739?cond="Carcinoma,+Endometrioid"&rank=3
Phase II Study of Mifepristone (RU-486) in the Treatment of PR Positive Advanced/Recurrent Endometrioid Adenocarcinoma and Low Grade Endometrial Stromal Sarcoma (LGESS)
0
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 121.8K Cancer specific
- 2.8K Anal Cancer
- 446 Bladder Cancer
- 309 Bone Cancers
- 1.6K Brain Cancer
- 28.5K Breast Cancer
- 397 Childhood Cancers
- 27.9K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 13K Head and Neck Cancer
- 6.4K Kidney Cancer
- 671 Leukemia
- 792 Liver Cancer
- 4.1K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 237 Multiple Myeloma
- 7.1K Ovarian Cancer
- 61 Pancreatic Cancer
- 487 Peritoneal Cancer
- 5.5K Prostate Cancer
- 1.2K Rare and Other Cancers
- 539 Sarcoma
- 730 Skin Cancer
- 653 Stomach Cancer
- 191 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.8K Uterine/Endometrial Cancer
- 6.3K Lifestyle Discussion Boards